Search

Your search keyword '"Kojima, Takashi"' showing total 3,457 results

Search Constraints

Start Over You searched for: Author "Kojima, Takashi" Remove constraint Author: "Kojima, Takashi"
3,457 results on '"Kojima, Takashi"'

Search Results

1. The implementation status of prehabilitation during neoadjuvant chemotherapy for patients with locally advanced esophageal cancer: a questionnaire survey to the board-certified facilities in Japan

9. EMPRESS. XII. Statistics on the Dynamics and Gas Mass Fraction of Extremely-Metal Poor Galaxies

10. JWST and ALMA Multiple-Line Study in and around a Galaxy at $z=8.496$: Optical to FIR Line Ratios and the Onset of an Outflow Promoting Ionizing Photon Escape

11. ALMA FIR View of Ultra High-redshift Galaxy Candidates at $z\sim$ 11-17: Blue Monsters or Low-$z$ Red Interlopers?

13. EMPRESS. IX. Extremely Metal-Poor Galaxies are Very Gas-Rich Dispersion-Dominated Systems: Will JWST Witness Gaseous Turbulent High-z Primordial Galaxies?

14. EMPRESS. VIII. A New Determination of Primordial He Abundance with Extremely Metal-Poor Galaxies: A Suggestion of the Lepton Asymmetry and Implications for the Hubble Tension

15. Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review

17. Subaru/FOCAS IFU revealed the metallicity gradient of a local extremely metal-poor galaxy

18. EMPRESS. IV. Extremely Metal-Poor Galaxies (EMPGs) Including Very Low-Mass Primordial Systems with M*=10^4--10^5 M_sun and 2--3% (O/H)_sun: High (Fe/O) Suggestive of Metal Enrichment by Hypernovae/Pair-Instability Supernovae

19. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial

21. Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathways

22. Application of Eggs in Food Product Development

25. Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial

26. Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807

27. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

29. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2

30. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma

32. EMPRESS. II. Highly Fe-Enriched Metal-poor Galaxies with $\sim 1.0$ (Fe/O)$_\odot$ and $0.02$ (O/H)$_\odot$ : Possible Traces of Super Massive ($>300 M_{\odot}$) Stars in Early Galaxies

33. EMPRESS. III. Morphology, Stellar Population, and Dynamics of Extremely Metal Poor Galaxies (EMPGs): Are EMPGs Local Analogs of High-$z$ Young Galaxies?

37. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy

38. Large Population of ALMA Galaxies at z>6 with Very High [OIII]88um to [CII]158um Flux Ratios: Evidence of Extremely High Ionization Parameter or PDR Deficit?

39. Extremely Metal-Poor Representatives Explored by the Subaru Survey (EMPRESS). I. A Successful Machine Learning Selection of Metal-Poor Galaxies and the Discovery of a Galaxy with M*<10^6 M_sun and 0.016 Z_sun

40. 3D Distribution Map of HI Gas and Galaxies Around an Enormous Ly$\alpha$ Nebula and Three QSOs at $z=2.3$ Revealed by the HI Tomographic Mapping Technique

41. Early Low-Mass Galaxies and Star-Cluster Candidates at z~6-9 Identified by the Gravitational Lensing Technique and Deep Optical/Near-Infrared Imaging

42. A Giant Green Pea Identified in the Spectroscopy of Spatially Extended [OIII] Sources

43. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

45. Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma

Catalog

Books, media, physical & digital resources